Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review

Atypical hemolytic uremic syndrome (aHUS) is a rare disease in pediatrics with 6-10% of cases associated with complement factor H autoantibodies. Ravulizumab is a new treatment option available for long-term management through blockage of the terminal complement cascade. We report a case of a previo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaoyan, Szarzanowicz, Amanda, Garba, Adinoyi, Schaefer, Beverly, Waz, Wayne R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665822/
https://www.ncbi.nlm.nih.gov/pubmed/34912617
http://dx.doi.org/10.7759/cureus.19476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665822/
https://www.ncbi.nlm.nih.gov/pubmed/34912617
http://dx.doi.org/10.7759/cureus.19476

Ejemplares similares